AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19112511 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine (OPV) at birth
Number of subjects: 4345
Study 19112511 — intervention group
Group type: COMPARATOR
Intervention: Not receiving OPV at birth (Control)
Number of subjects: 4345
Study 15853109 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond dual cure (OPTB) with light-curing (LC) and combination of light and chemical curing (LCC)
Number of subjects: 72
Study 15853109 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-curing (LC) and combination of light and chemical curing (LCC)
Number of subjects: 72
Study 12816339 — intervention group
Group type: EXPERIMENTAL
Intervention: context/specific questions
Number of subjects: 236
Study 12816339 — intervention group
Group type: COMPARATOR
Intervention: noncontext/label questions
Number of subjects: 236
Study 12816339 — intervention group
Group type: COMPARATOR
Intervention: noncontext/specific questions
Number of subjects: 236
Study 12816339 — intervention group
Group type: COMPARATOR
Intervention: context/label questions
Number of subjects: 236
Study 10676865 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2 added to the inspiratory gas mixture
Number of subjects: 30
Study 10676865 — intervention group
Group type: COMPARATOR
Intervention: Increased venous pressure to fill the pulmonary vascular bed
Number of subjects: 30
Study 9060198 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention programme
Number of subjects: 60
Study 9060198 — intervention group
Group type: COMPARATOR
Intervention: Discussion control group
Number of subjects: 60
Study 9060198 — intervention group
Group type: COMPARATOR
Intervention: No-additional treatment control group
Number of subjects: 60
Study 8457152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (20-Gy) + postoperative low-dose external-beam radiotherapy (35- to 40-Gy)
Number of subjects: 35
Study 8457152 — intervention group
Group type: COMPARATOR
Intervention: Postoperative high-dose external-beam radiotherapy (50- to 55-Gy) alone (Control)
Number of subjects: 35
Study 3636335 — intervention group
Group type: EXPERIMENTAL
Intervention: Timentin alone
Number of subjects: 100
Study 3636335 — intervention group
Group type: EXPERIMENTAL
Intervention: Timentin in combination with amikacin
Number of subjects: 100
Study 29855611 — intervention group
Group type: EXPERIMENTAL
Intervention: RT Prepare intervention (two consultations with a radiation therapist)
Number of subjects: 408
Study 29855611 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 408
Study 28821271 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed resistance training
Number of subjects: 30
Study 28821271 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed resistance training plus balance exercises
Number of subjects: 30
Study 28821271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 26073872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine 2 mg
Number of subjects: 768
Study 26073872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine 1 mg
Number of subjects: 768
Study 26073872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study 22903360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention for body image disturbance
Number of subjects: 38
Study 22903360 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 38
Study 21696738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 33
Study 21696738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 21696738 — intervention group
Group type: EXPERIMENTAL
Intervention: High Hcy
Number of subjects: 33
Study 21696738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Hcy
Number of subjects: 33
Study 18326731 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.4 mg/kg bolus followed by 0.4 mg/kg/h continuous infusion for 120 minutes)
Number of subjects: 12
Study 16782912 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg by mouth twice daily)
Number of subjects: 78
Study 16782912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 12932066 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia with hyperbaric bupivacaine 7.5 mg 0.5% (Group Spinal)
Number of subjects: 30
Study 12932066 — intervention group
Group type: COMPARATOR
Intervention: Volatile induction and maintenance anaesthesia with sevoflurane (Group SEVO)
Number of subjects: 30
Study 11119192 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (12 mg.kg(‐1).h(‐1)) and alfentanil (0.04 mg.kg(‐1).h(‐1))
Number of subjects: 39
Study 11119192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1-1.2 MAC in 30% O(2)/70% N(2)O
Number of subjects: 39
Study 11119192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine racemate (10-12 mg.kg(‐1).h(‐1)) and midazolam (0.3-0.6 mg.kg(‐1).h(‐1))
Number of subjects: 39
Study 11119192 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 1-1.2 MAC in 30% O(2)/70% N(2)O
Number of subjects: 39
Study 9194018 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential-existential group psychotherapy (EEGP) program for 13 weeks
Number of subjects: 0
Study 9194018 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WLC) condition
Number of subjects: 0
Study 8241695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone (coenzyme Q10), 100 mg/day for 7 months
Number of subjects: 0
Study 31563743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention based on the Transtheoretical Model and Paulo Freire's pedagogy, consisting of 12 educational activities over 7 months.
Number of subjects: 1483
Study 31563743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 1483
Study 29212528 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted training using the Armeo®Spring robot for 3 weeks
Number of subjects: 0
Study 29212528 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational and physical therapy
Number of subjects: 0
Study 25575541 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus recombinant human thrombopoietin (rhTPO)
Number of subjects: 115
Study 25575541 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 115
Study 25637728 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated protocol (ACCEL)
Number of subjects: 40
Study 25637728 — intervention group
Group type: COMPARATOR
Intervention: Slow protocol (SLOW)
Number of subjects: 40
Study 23513469 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh lime
Number of subjects: 100
Study 23513469 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 100
Study 19880138 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (not specified dosage or duration)
Number of subjects: 191
Study 19880138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 191
Study 17696962 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose esomeprazole (40 mg b.d.)
Number of subjects: 240
Study 17696962 — intervention group
Group type: COMPARATOR
Intervention: Low-dose esomeprazole (40 mg o.d.)
Number of subjects: 240
Study 17696962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study 16139581 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vagus nerve stimulation (VNS) for 12 months
Number of subjects: 202
Study 16139581 — intervention group
Group type: COMPARATOR
Intervention: Sham vagus nerve stimulation (VNS) for 12 months
Number of subjects: 202
Study 11930093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Medical Therapy (IMT)
Number of subjects: 87
Study 11930093 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Toilet Training (ETT)
Number of subjects: 87
Study 11930093 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 87
Study 9799346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sestamibi
Number of subjects: 400
Study 9799346 — intervention group
Group type: COMPARATOR
Intervention: Tetrofosmin
Number of subjects: 400
Study 8746103 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbasalate+metoclopramide (CSC-METO)
Number of subjects: 155
Study 8746103 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine mesilate (DHE)
Number of subjects: 155
Study 2565728 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg WY-45,727
Number of subjects: 20
Study 2565728 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg WY-45,727
Number of subjects: 20
Study 2565728 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg WY-45,727
Number of subjects: 20
Study 2565728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 589917 — intervention group
Group type: EXPERIMENTAL
Intervention: Double contrast barium meal
Number of subjects: 206
Study 589917 — intervention group
Group type: COMPARATOR
Intervention: Single contrast barium meal
Number of subjects: 206
Study 31189785 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P (SSTP) intervention
Number of subjects: 36
Study 31189785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 28188086 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group A (150 mg oral vismodegib per day for 12 weeks, then three rounds of 8 weeks of placebo daily followed by 12 weeks of 150 mg vismodegib daily)
Number of subjects: 229
Study 28188086 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group B (150 mg oral vismodegib per day for 24 weeks, then three rounds of 8 weeks of placebo daily followed by 8 weeks of 150 mg vismodegib daily)
Number of subjects: 229
Study 28188086 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (A and B)
Number of subjects: 229
Study 28188086 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group A
Number of subjects: 229
Study 28188086 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group B
Number of subjects: 229
Study 26776900 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR video self-instruction materials
Number of subjects: 653
Study 26776900 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 653
Study 25068884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL; 1.7 g·kg(‐1)·day(‐1) for 7 days)
Number of subjects: 15
Study 25068884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn flour)
Number of subjects: 15
Study 25068884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL)
Number of subjects: 15
Study 22946607 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for caregivers (CGs)
Number of subjects: 32
Study 22946607 — intervention group
Group type: COMPARATOR
Intervention: Minimal support with individualized access to relevant online information (Control)
Number of subjects: 32
Study 19721045 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT-CT imaging
Number of subjects: 20
Study 19721045 — intervention group
Group type: COMPARATOR
Intervention: CT and bone scanning together
Number of subjects: 20
Study 17284630 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine 200 microg/d (group S1)
Number of subjects: 2143
Study 17284630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group S0)
Number of subjects: 2143
Study 17284630 — intervention group
Group type: COMPARATOR
Intervention: Control group (TPOAb(-) age-matched women, group C)
Number of subjects: 2143
Study 15510897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 3 x 0.5 mg
Number of subjects: 45
Study 15510897 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 3 x 2 mg
Number of subjects: 45
Study 11479694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 levels in lung cancer patients
Number of subjects: 69
Study 11479694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 levels in squamous cell and adenocarcinoma varieties
Number of subjects: 69
Study 11479694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 specificity and sensitivity
Number of subjects: 69
Study 11479694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 sensitivity for NSCLC
Number of subjects: 69
Study 11479694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 sensitivity in advanced stages of squamous cell lung cancer
Number of subjects: 69
Study 11479694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 levels after treatment in NSCLC patients
Number of subjects: 69
Study 9916589 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal laparoscopic repair (TEP)
Number of subjects: 292
Study 9916589 — intervention group
Group type: COMPARATOR
Intervention: Mesh-plug hernioplasty
Number of subjects: 292
Study 9916589 — intervention group
Group type: COMPARATOR
Intervention: Open-surgery group
Number of subjects: 292
Study 8303945 — intervention group
Group type: EXPERIMENTAL
Intervention: Lederle/Takeda acellular pertussis component diphtheria‐tetanus‐pertussis vaccine (APDT)
Number of subjects: 149
Study 8303945 — intervention group
Group type: COMPARATOR
Intervention: Lederle whole‐cell pertussis component diphtheria‐tetanus‐pertussis vaccine (DTP)
Number of subjects: 149
Study 2498507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional recombinant tumor necrosis factor-alpha (rTNF) at a recommended dose of 25 micrograms/m2
Number of subjects: 27
Study 2498507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30296436 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation of the post-EMR mucosal defect margin (n = 210)
Number of subjects: 390
Study 30296436 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (controls, n = 206)
Number of subjects: 390
Study 27761981 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate bicarbonate of 34 mmol/L
Number of subjects: 93
Study 27761981 — intervention group
Group type: COMPARATOR
Intervention: Dialysate bicarbonate of 30 mmol/L
Number of subjects: 93
Study 25005172 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Review (LR) intervention
Number of subjects: 55
Study 25005172 — intervention group
Group type: COMPARATOR
Intervention: Active Control (AC) group (media workshop)
Number of subjects: 55
Study 24456438 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic single-dose antibiotics
Number of subjects: 0
Study 24456438 — intervention group
Group type: COMPARATOR
Intervention: Prolonged course of antibiotics
Number of subjects: 0
Study 22108776 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) during tuberculosis treatment
Number of subjects: 58
Study 22108776 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) off tuberculosis treatment
Number of subjects: 58
Study 22108776 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow metabolizers with tuberculosis treatment
Number of subjects: 58
Study 22108776 — intervention group
Group type: COMPARATOR
Intervention: Slow metabolizers without tuberculosis treatment
Number of subjects: 58
Study 22108776 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of tuberculosis treatment on EFV clearance
Number of subjects: 58
Study 19542314 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated methods
Number of subjects: 62
Study 19542314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated method
Number of subjects: 62
Study 19542314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 17582145 — intervention group
Group type: EXPERIMENTAL
Intervention: UAE
Number of subjects: 177
Study 17582145 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study 15837406 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diffuse FIL (n=40)
Number of subjects: 40
Study 15837406 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (n=50)
Number of subjects: 40
Study 15837406 — intervention group
Group type: COMPARATOR
Intervention: Comparison between patients and control group
Number of subjects: 40
Study 15837406 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with FIL
Number of subjects: 40
Study 11874228 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐minute, 3 times per week, jumping program
Number of subjects: 174
Study 11874228 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study 10077258 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 102
Study 10077258 — intervention group
Group type: COMPARATOR
Intervention: Control (no chewing gum)
Number of subjects: 102
Study 8838387 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 trials of training on the rotary pursuit task
Number of subjects: 24
Study 8838387 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 trials of training on the rotary pursuit task
Number of subjects: 24
Study 8838387 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 trials of training on the rotary pursuit task
Number of subjects: 24
Study 8838387 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention tests conducted 20 min, 2 days, 7 days, and 37 days after practice
Number of subjects: 24
Study 8838387 — intervention group
Group type: EXPERIMENTAL
Intervention: AD patients
Number of subjects: 24
Study 8838387 — intervention group
Group type: COMPARATOR
Intervention: Healthy older adults
Number of subjects: 24
Study 1911021 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08% bupivacaine 8 ml
Number of subjects: 3
Study 1911021 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline 8 ml
Number of subjects: 3
Study 1911021 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 3
Study 6811766 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 97
Study 6811766 — intervention group
Group type: COMPARATOR
Intervention: Megavoltage radiation therapy
Number of subjects: 97
Study 30929060 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not provided)
Number of subjects: 173
Study 30929060 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma BDNF levels
Number of subjects: 173
Study 30929060 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BDNF exon IV promoter and p11 gene methylation status
Number of subjects: 173
Study 31587995 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg escitalopram/day in addition to structured psychosocial intervention (PSI)
Number of subjects: 0
Study 31587995 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo in addition to structured psychosocial intervention (PSI)
Number of subjects: 0
Study 27987385 — intervention group
Group type: EXPERIMENTAL
Intervention: MICA mismatched HLA 10/10 donors
Number of subjects: 713
Study 27987385 — intervention group
Group type: EXPERIMENTAL
Intervention: MICA mismatches
Number of subjects: 713
Study 27987385 — intervention group
Group type: COMPARATOR
Intervention: MICA polymorphism (MICA-129)
Number of subjects: 713
Study 25499548 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counselling programme (12 weeks)
Number of subjects: 155
Study 25499548 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 155
Study 23447850 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-vision goggles (NVG)
Number of subjects: 5
Study 23447850 — intervention group
Group type: COMPARATOR
Intervention: Standard helmet mockup (control)
Number of subjects: 5
Study 22137082 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise training
Number of subjects: 49
Study 22137082 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 19846844 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of nonadjuvanted vaccine
Number of subjects: 2200
Study 19846844 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg of vaccine (with or without adjuvant)
Number of subjects: 2200
Study 19846844 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine without adjuvant
Number of subjects: 2200
Study 19846844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2200
Study 16907966 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched cereal bars (50 mg isoflavones/day; genistein to daidzein ratio 2:1)
Number of subjects: 34
Study 16907966 — intervention group
Group type: COMPARATOR
Intervention: Non-isoflavone-enriched control bars
Number of subjects: 34
Study 15109513 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg/day
Number of subjects: 34
Study 15109513 — intervention group
Group type: COMPARATOR
Intervention: Citalopram 20 mg/day
Number of subjects: 34
Study 15109513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11717605 — intervention group
Group type: EXPERIMENTAL
Intervention: COER verapamil 180 to 540 mg once daily in the evening for up to 10 weeks
Number of subjects: 1999
Study 11717605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1999
Study 11717605 — intervention group
Group type: COMPARATOR
Intervention: Active comparator agent
Number of subjects: 1999
Study 9553866 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ketorolac tromethamine oral rinse, twice daily for 6 months
Number of subjects: 0
Study 9553866 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 7894000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfacalcidol (4 micrograms, thrice-weekly for 6 weeks)
Number of subjects: 16
Study 7894000 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alfacalcidol (4 micrograms, thrice-weekly for 6 weeks)
Number of subjects: 16
Study 7894000 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alfacalcidol
Number of subjects: 16
Study 7894000 — intervention group
Group type: COMPARATOR
Intervention: Oral alfacalcidol
Number of subjects: 16
Study 2449022 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium chloride hexahydrate 25% in ethanol
Number of subjects: 30
Study 31646727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide device
Number of subjects: 310
Study 29602430 — intervention group
Group type: EXPERIMENTAL
Intervention: Health game Fume
Number of subjects: 151